Evidence map›Paper›PMID 37290717›Full record

ArticleProtein expression and purification2023

Isolation of recombinant apolipoprotein E4 N-terminal domain by foam fractionation.

Kyle Lethcoe, Colin A Fox, Anouar Hafiane, Robert S Kiss, Robert O Ryan

Open access · greenAbstract read
In one paragraph

Article in Protein expression and purification, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Foam fractionation studies of recombinant human apolipoprotein A-I.Biochimica et biophysica acta. Biomembranes · 2024
    Article
  2. Characterization ofMetabolites · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Kyle LethcoeDepartment of Biochemistry and Molecular Biology, University of Nevada, Reno, NV, 89557, USA.
Colin A FoxDepartment of Biochemistry and Molecular Biology, University of Nevada, Reno, NV, 89557, USA.
Anouar HafianeDepartment of Medicine, Division of Cardiology, McGill University, Montreal, QC, Canada.
Robert S KissDepartment of Medicine, Division of Cardiology, McGill University, Montreal, QC, Canada.
Robert O RyanDepartment of Biochemistry and Molecular Biology, University of Nevada, Reno, NV, 89557, USA. Electronic address: robertryan@unr.edu.
University of Nevada, Reno · USMcGill University · CA

Funding

Effect of Apolipoprotein Structural AdaptabilityR37HL064159 · NHLBI · UNIVERSITY OF NEVADA RENO · PI RYAN, ROBERT O'MARA · 2010 to 2019
$4.1M
NHLBI NIH HHS R37 HL064159
6 · The paper itself

Abstract

Apolipoprotein (apo) E functions in lipoprotein metabolism as a low density lipoprotein receptor ligand. ApoE is comprised of two structural domains, a 22 kDa N-terminal (NT) domain that adopts a helix bundle conformation and a 10 kDa C-terminal domain with strong lipid binding affinity. The NT domain is capable of transforming aqueous phospholipid dispersions into discoidal reconstituted high density lipoprotein (rHDL) particles. Given the utility of apoE-NT as a structural component of rHDL, expression studies were conducted. A plasmid construct encoding a pelB leader sequence fused to the N-terminus of human apoE4 (residues 1-183) was transformed into Escherichia coli. Upon expression, the fusion protein is directed to the periplasmic space where leader peptidase cleaves the pelB sequence, generating mature apoE4-NT. In shaker flask expression cultures, apoE4-NT escapes the bacteria and accumulates in the medium. In a bioreactor setting, however, apoE4-NT was found to combine with gas and liquid components in the culture medium to generate large quantities of foam. When this foam was collected in an external vessel and collapsed into a liquid foamate, analysis revealed that apoE4-NT was the sole major protein present. The product protein was further isolated by heparin affinity chromatography (60-80 mg/liter bacterial culture), shown to be active in rHDL formulation, and documented to serve as an acceptor of effluxed cellular cholesterol. Thus, foam fractionation provides a streamlined process to produce recombinant apoE4-NT for biotechnology applications.

Indexed as

Apolipoprotein E4Apolipoproteins ECarrier ProteinsHumansRecombinant ProteinsApolipoprotein E4Apolipoproteins ECarrier ProteinsRecombinant ProteinsApolipoprotein EBioreactorFoam fractionationNanodiscNanodiskReconstituted high density lipoprotein

Identifiers

PMID37290717
PMCPMC10330888
OpenAlexW4379520662

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.